热门资讯> 正文
Alcon收购LumiThera及其光生物调节装置，用于治疗早期和中期干性视网膜相关性视网膜病变;数量未透露
2025-07-07 20:15
- LumiThera's photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients1,2
- Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4
- Alcon aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with retinal diseases
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
